Q4 2022 Results

Company overview Innovation: Pipeline overview Cardiovascular iptacopan - CFB inhibitor NCT03955445 (CLNP023B12001B) Financial review Immunology 2023 priorities Innovation: Clinical trials Neuroscience Oncology iptacopan - CFB inhibitor NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 Appendix Abbreviations Other Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Indication Phase Patients C3 glomerulopathy (C3G) Phase 2 Indication Phase Primary Outcome Measures Target Patients Readout Arms Intervention 27 patients from ongoing Ph2 (sample size from Ph3 pending HA discussions Q1 2021), total patients for this study will increase Characterize the effect of LNP023 treatment on a composite renal response endpoint at 9 months (1. a stable or improved eGFR and, 2. a reduction in proteinuria and 3. an increase in C3 compared to the CLNP023X2202 baseline visit) Open-label LNP023 200mg bid Patients with C3 glomerulopathy Patients 68 Primary Outcome Measures Arms Intervention Target Patients Readout Milestone(s) 2023 2025 Milestone(s) Publication TBD Publication Wong et al 2021 Nephrology, Dialysis and Transplantation Vol. 36, Suppl. 1: eGFR trajectory 62 Investor Relations | Q4 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation